Catalent eyes acquisitions in emerging market and drug delivery expansion

By Nick Taylor

- Last updated on GMT

Related tags: Investment

Catalent is considering acquisitions as it adds scale, drug delivery technologies and capacity in emerging markets.

The shift towards more strategic outsourcing and greater reliance on vendors is driving pursuit of scale, geographic reach and advanced capabilities at Catalent. To meet some of these goals Catalent made a $410m (€296m) move for Aptuit’s clinical trial supply assets and further deals are possible.

If there’s an opportunity for us to pick up an inorganic acquisition at the right time and the right place we will certainly do that​”, Scott Houlton, president, development and clinical services at Catalent, told Outsourcing-Pharma.

Houlton outlined areas of expansion at Catalent: “We will continue to invest in drug delivery technologies and also in scale. I think there are opportunities for us to look at the emerging markets, within China, India, other locations​.”

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Related suppliers

Follow us


View more